Synopsis:-Reporting audited FY26 results on 26 May 2026, Venus Remedies Limited posted consolidated PAT of Rs. 102.78 crore more than double the prior year alongside zero outstanding debt and the company’s first dividend in several years, while the board also elevated Saransh Chaudhary as Whole Time Director in a generational shift at the leadership level.
A Panchkula-based injectable pharmaceutical manufacturer and antibiotic specialist came into focus after its board approved a packed slate of decisions at a marathon six-hour meeting on May 26, 2026. The audited FY26 results delivered consolidated net profit that crossed Rs. 100 crore for the first time in recent history, while the company simultaneously confirmed a zero-debt balance sheet and proposed its first dividend in years three simultaneous signals of a business that has materially restructured since its loss-making years of FY17–FY20.
With a market capitalization of Rs. 1,629.57 crore, the shares of Venus Remedies Limited were trading at Rs. 1,219.1 per share, up 5 percent from its previous close of Rs. 1,161.05. It is trading at a P/E of 15.1.
Consolidated revenue from operations rose 17.9 percent year-on-year to Rs. 769.60 crore in FY26 from Rs. 652.89 crore in FY25. EBITDA nearly doubled to Rs. 159.86 crore from Rs. 84.48 crore, with margins expanding sharply a reflection of a richer product mix tilted toward higher-value antibiotics and antimicrobial resistance drugs. Consolidated PAT for FY26 came in at Rs. 102.78 crore versus Rs. 45.31 crore in FY25 a 127 percent increase, with no exceptional items distorting the figure in either direction. Consolidated EPS rose to Rs. 76.89 from Rs. 33.89.
The quarter was the standout: standalone revenue in Q4 FY26 was Rs. 259.01 crore, the highest single quarter visible in the available data, up 31.7 percent from Rs. 196.74 crore in Q4 FY25. Q4 standalone PAT of Rs. 43.45 crore was nearly three times the Rs. 14.79 crore reported a year earlier. Full-year standalone PAT of Rs. 99.31 crore also crossed the Rs. 100 crore mark in round terms.
On the balance sheet, the company’s outstanding borrowings as at 31 March 2026 are declared as nil confirmed in a separate undertaking to the exchanges. This is a complete reversal from a debt position that once approached Rs. 335 crore and drove the company into losses through FY20. During FY26, the company deployed Rs. 152.56 crore into mutual funds and fixed deposits, indicating substantial liquidity accumulation. Capital work-in-progress doubled from Rs. 26.39 crore to Rs. 51.36 crore, suggesting active capacity expansion is underway alongside the cash build-up.
One item disclosed in the notes merits flagging: the company’s investment in its German subsidiary Venus Pharma GmbH remains pending for formal share allotment, as such allotment is not mandated under German regulations. Management has engaged a Germany-based financial consultancy to advise on the appropriate mechanism. This is a routine compliance matter under foreign law, but investors should note it as an unresolved item in the subsidiary structure.
The board has recommended a final dividend of Rs. 10 per equity share 100 percent on the face value of Rs. 10 for FY26, subject to shareholder approval at the 37th AGM scheduled for 20 August 2026 via video conferencing. The record date is 7 August 2026. The company recorded zero dividend payout in every year from at least FY15 through FY25; this dividend marks the first shareholder return of this kind after a long hiatus, and signals management’s confidence in the sustainability of current cash generation.
Business Overview
Incorporated in 1989 and listed on both BSE and NSE, Venus Remedies is a research-based injectable pharmaceutical company and one of India’s largest manufacturers of meropenem-class antibiotics. The company holds over 135 patents and 1,040 marketing authorisations globally, with products spanning anti-infectives, antimicrobial resistance, oncology, neurology, and wound care. It operates manufacturing facilities in Panchkula and Baddi, and has a German subsidiary (Venus Pharma GmbH) along with a Hungary-based step-down subsidiary.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
